Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T. Fathi, Yi‐Bin Chen, Eyal C. Attar et al.|Haematologica|2016Cited by 43
Isocitrate dehydrogenase 1 and 2 mutations, 2‐hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemiaAndrew M. Brunner, Amir Fathi, Donna Neuberg et al.|Cancer|2018Cited by 33
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutationAmir T. Fathi, Mark J. Levis, Traci M. Blonquist et al.|Cancer|2017Cited by 31
Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid LeukemiaAndrew M. Brunner, Amir Fathi, Donna Neuberg et al.|Blood|2015Cited by 6
A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid LeukemiaAmir T. Fathi, Philip C. Amrein, Traci M. Blonquist et al.|Blood|2016Cited by 4